Our Centres
Our Doctors
Your state: SA |
Our Centres
Our Doctors
Dr Qurrat van den Blink
MBCHB hons, MRCP, FRCR, FRANZCR, Radiation Oncologist
For patients/carers
For doctors
MBCHB hons, MRCP, FRCR, FRANZCR, Radiation Oncologist
Locations
Clinical interests
- Head and neck cancer
- Lung cancer
- Breast cancer
- Skin cancer
- Metastatic cancer
- Benign conditions
- Oligometastatic tumours
Languages
Fluent
- English
- Urdu / اردو
- Punjabi / ਪੰਜਾਬੀ
Biography
Clinical interest in Lung, head and neck, skin, breast, prostate, gastrointestinal (GI), and oligometastatic tumours.
Dr van den Blink is a UK trained doctor who received her medical degree from the University of Liverpool in 2003. She completed physician training and specialist training in Clinical Oncology at The Christie Hospital, Manchester, UK and Lancashire Teaching hospital, Preston, UK. She was recognised in 2012 with the Best Young Scientist Poster Award, at ESTRO 31, in Barcelona. Further, Dr van den Blink developed a clinical interest in lung cancer and alsostereotactic radiation therapy technology through her fellowship and ongoing affiliation with the Princess Margaret Cancer Centre, Toronto, Canada in 2013 to 2015. As a Consultant Clinical Oncologist, she has experience in managing and head and neck cancers and patients with oligometastatic disease.
Dr van den Blink relocated to Australia in 2020, undertaking fellowships at Sir Charles Gairdner Hospital (SCGH) in Perth and Princess Alexandra Hospital, Brisbane and was awarded her fellowship of the Royal Australian and New Zealand College of Radiologists (RANZCR) in 2022.
Dr van den Blink is a trained educator and supervisor involved in clinical and lecture-based teaching of training registrars, medical students and junior doctors. She strives to offer high-quality, patient-centred care, aiming to deliver the best possible clinical outcomes.
More information
- Lung stereotactic radiotherapy research fellowship and ongoing affiliation with the Princess Margaret Cancer Centre, Toronto, Canada in 2013 to 2015
- Stereotactic radiotherapy in combination with immunotherapy and biological agents
- Reducing treatment related toxicities
- Royal Australian and New Zealand College of Radiologists (RANZCR)
- Australian and New Zealand Head & Neck Cancer Society (ANZHNCS)
- European Society for Radiotherapy and Oncology (ESTRO)
- American Society for Radiation Oncology (ASTRO)
- van den Blink, Q., Garcez, K., Henson, C. C., Davidson, S. E., & Higham, C. E. (2018). Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis associated with pelvic radiotherapy in adults. Cochrane Database of Systematic Reviews, (4), Article CD010604. https://doi.org/10.1002/14651858.CD010604.pub2
- Nutting, C. M., Morden, J. P., Beasley, M., Bhide, S., Cook, A., De Winton, E., Emson, M., Evans, M., Fresco, L., Gollins, S., Gujral, D., Harrington, K., Joseph, M., Lemon, C., Luxon, L., van den Blink, Q., Mendes, R., Miah, A., Newbold, K., Prestwich, R., Robinson, M., Sanghera, P., Simpson, J., Sivaramalingam, M., Srihari, N. N., Sydenham, M., Wells, E., Witts, S., & Hall, E. (2018). Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer. European Journal of Cancer, 103, 249–258. https://doi.org/10.1016/j.ejca.2018.08.004
Best Young Scientist Poster Award, ESTRO 31, Barcelona, Spain (2012).
